You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a blood test for breast cancer detection

    SBC: INTEGRATED TECHNOLOGIES AND SRVCS INTRNTL            Topic: N/A

    DESCRIPTION (provided by applicant): Mammography is the benchmark for breast disease detection and diagnosis. However, it can miss 10-15% of early stage breast cancers, and it is unable to distinguish between benign and malignant lesions with certainty. Av ailability of an alternate method e.g. biomarker based, which allows early detection/precise distinction between benign disease and breast canc ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Inhibitors of Latent Epstein Barr Virus Infection

    SBC: VIRONIKA LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The product that will result from this SBIR program, proposed by Vironika and its consortium partner, The Wistar Institute, is a new (the first) small molecule drug candidate for Epstein-Barr virus (EBV) latent infection, and its associated pathologies. EBV is a prevalent human herpesvirus that has been classified by the World Health Organization as a human car ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  3. N/A

    SBC: ANNOVIS, INC.            Topic: N/A

    N/A

    SBIR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  4. Sphingosine Kinase Inhibitors as Anti-Arthritis Agents

    SBC: Apogee Biotechnology Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Sphingolipids are being increasingly recognized as key mediators of inflammatory cascades of critical importance in multiple diseases, including rheumatoid arthritis and osteoarthritis. Most importantly, sphingosine 1-phosphate produced by sphingosine kinase (SK) mediates the effects of tumor necrosis factor-1 and interleukin-12, pro-inflammatory cytokines ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  5. ZigBee-Based System for Rapid and Efficient Communication and Emergency Response

    SBC: Touchtown Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Fast and effective communication is the key to minimizing confusion, anxiety, and casualties both during and after a public health emergency. The ability of emergency services personnel to relay clear instructions, part icularly to vulnerable populations, results in better understanding of the situation by the population and faster compliance with these instruc ...

    SBIR Phase I 2009 Department of Health and Human ServicesCenters for Disease Control and Prevention
  6. A Modulator of Innate Immunity for Preventing Hospital-Acquired Infections

    SBC: THERIMUNEX PHARMACEUTICALS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The product that will result from this proposal will be a potent biological regulator of innate immunity, 1- peptidyl-2,3-diacylglyceride (PDAG), for use in the prevention of hospital-acquired (nosocomial) infections in highly-susceptible patient populations. Nosocomial infection is a rapidly growing cause of morbidity and mortality in U.S. hospitals and nosoc ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Care monitor system to facilitate pressure ulcer prevention for the elderly

    SBC: AUGMENTECH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): To reduce the incidence of pressure ulcers, administrators of long term care facilities must identify which care processes need improvement and measure if their management interventions are effective. Currently, this is difficult because the reliability of care delivery is overestimated in patients' charts and medical records. Most of the physical body care of ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Radiopharmaceuticals for Imaging Brain Tau Pathology

    SBC: AVID RADIOPHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with more than 4.5 million Americans currently suffering from the disease. Clinical management of AD is complicated by lack of effective meth ods for early and accurate diagnosis of the disease. Thus, there is a significant unmet need for Alzheimer's disease diagnostic tools. The hypo ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. 18F-AV-133, A Novel Radiopharmaceutical for Differential Diagnosis of Dementia

    SBC: AVID RADIOPHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Dementia, with its most prevalent subforms Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and vascular dementia, is a very substantial medical and societal problem. The emergence of many drugs and drug can didates that interfere with the disease mechanism of specific types of dementia makes it crucial to distinguish early between the various forms ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. 18F-AV-45 PET Imaging of Amyloid in PD with Cognitive Impairment

    SBC: AVID RADIOPHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Dementia associated with PD (PDD) is common (affecting up to 80% of patients long-term) and highly disabling. Informative biomarkers are urgently needed to understand the pathology of PDD, to improve the early detection of cognitive deficits and to facilitate the development of treatments for PDD. Nuclear imaging technologies have the potential to produce such ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government